| ID | 10016 |
| Vaccine Name | Covishield |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Approved |
| Manufacturer | AstraZeneca plc, University of Oxford, Serum Institute of India |
| Year of Manufacturing | NA |
| Manufacturing Country | NA |
| Age | NA |
| Dosage | 2 doses 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria |
| PMID | 33816047 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | NA
|